Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
New England Journal of Medicine · 21.08.2025 · 393 (8) · 764-773
DOI: 10.1056/nejmoa2410542 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 21.08.2025. Verfasst von Bruce C Trapnell und 24 weiteren Autor:innen. Beteiligte Einrichtung: Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati. Hauptthemen laut MEDLINE: Autoimmune Diseases, Granulocyte-Macrophage Colony-Stimulating Factor, Pulmonary Alveolar Proteinosis. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Savara Inc..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Translational Pulmonary Science Center, Cincinnati Children's Hospital Medical Center, Cincinnati.
- Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.
- Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
- Internal Medicine, Osaka Anti-Tuberculosis Association, Osaka Fukujuji Hospital, Osaka, Japan.
- Center for Interstitial and Rare Lung Diseases, Pneumology Department, Ruhrlandklinik University Hospital, University of Duisburg-Essen, Essen, Germany.
ORCID-Profile: Bruce C Trapnell, Yoshikazu Inoue, Francesco Bonella
Förderung
- Savara Inc.
Zitieren
APA
Trapnell, B. C., Inoue, Y., Bonella, F., Wang, T., McCarthy, C., Arai, T., Akasaka, K., Mariani, F., Mogulkoc, N., Song, J. W., Baba, T., Jouneau, S., Numakura, T., Öcal, N., Mihaltan, F., Ataya, A., Bendstrup, E., Campo, I., Carey, B., …, & IMPALA-2 Trial Investigators (2025). Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine, 393(8), 764-773. https://doi.org/10.1056/nejmoa2410542
Vancouver
Trapnell BC, Inoue Y, Bonella F, Wang T, McCarthy C, Arai T, et al. Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis. New England Journal of Medicine. 2025;393(8):764-773. doi:10.1056/nejmoa2410542
BibTeX
@article{Trapnell2025,
author = {Trapnell, Bruce C and Inoue, Yoshikazu and Bonella, Francesco and Wang, Tisha and McCarthy, Cormac and Arai, Toru and Akasaka, Keiichi and Mariani, Francesca and Mogulkoc, Nesrin and Song, Jin Woo and Baba, Tomohisa and Jouneau, Stephane and Numakura, Tadahisa and Öcal, Nesrin and Mihaltan, Florin and Ataya, Ali and Bendstrup, Elisabeth and Campo, Ilaria and Carey, Brenna and Arena, Ross and Robinson, Brian and Fleming, Rosanna and Wasfi, Yasmine and Pratt, Raymond and IMPALA-2 Trial Investigators, IMPALA-2 Trial Investigators},
title = {Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {8},
pages = {764--773},
doi = {10.1056/nejmoa2410542}
}
EUVIMED